Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma
Open Access
- 30 November 2012
- journal article
- Published by Spandidos Publications in Oncology Reports
- Vol. 29 (2), 685-689
- https://doi.org/10.3892/or.2012.2162
Abstract
Cystine/glutamic acid transporter (xCT) plays a role in tumor progression by regulating the redox status in several types of cancers. To demonstrate the importance of xCT expression for predicting the prognosis of hepatocellular carcinoma (HCC), we analyzed xCT gene expression in 130 paired HCC and non-cancerous tissues. xCT protein expression was confirmed using 7 HCC cell lines and samples from human subjects. xCT mRNA expression was detected in 34 (26%) tumor tissues. Expression of xCT was higher in HCC tissues compared to the corresponding normal tissues according to quantitative reverse transcriptase-polymerase chain reaction findings (P<0.0001). Patients in the group presenting with xCT mRNA expression showed poorer overall and disease-free survival than did those with an absence of xCT mRNA (P=0.0130 and 0.0416, respectively). xCT mRNA expression proved to be an independent factor for poor prognosis in a multivariate analysis of overall survival (hazard ratio, 1.68; 95% CI, 1.03-2.92). We observed xCT protein expression in both the HCC cell lines and in human tissue samples. In conclusion, the findings of the present study suggest that xCT is useful as a predictive marker for patient prognosis and that it may be a novel therapeutic target for HCC.Keywords
This publication has 23 references indexed in Scilit:
- Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognosesBMC Cancer, 2009
- Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyondPharmacology & Therapeutics, 2009
- xCT expression reduces the early cell cycle requirement for calcium signalingCellular Signalling, 2008
- The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseasesJournal of Cellular Physiology, 2008
- Autocrine Glutamate Signaling Promotes Glioma Cell InvasionCancer Research, 2007
- Sulfasalazine-Induced Reduction of Glutathione Levels in Breast Cancer Cells: Enhancement of Growth-Inhibitory Activity of DoxorubicinChemotherapy, 2007
- Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapyThe Prostate, 2006
- Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyAnnals Of The Rheumatic Diseases, 2006
- Influence of the Extracellular Glutamate Concentration on the Intracellular Cyst(e)ine Concentration in Macrophages and on the Capacity to Release CysteineBiological Chemistry Hoppe-Seyler, 1989
- Role of membrane transport in metabolism and function of glutathione in mammalsThe Journal of Membrane Biology, 1986